

## **ESC Declaration of Interest Report**

### **2023 ESC Guidelines for the management of acute coronary syndromes**

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs presented in this report were assessed prior to work commencing and during the development of the work, according to the applicable review criteria in place at the time and as defined in the ESC Declaration and Management of Conflict of Interest Policy, Annex 3.

The most up-to-date version of the policy and its annexes are available on the ESC website at [www.escardio.org/DOI](http://www.escardio.org/DOI).

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Barbato Emanuele	<p><b>2020</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            GE Healthcare : Coronary physiology            Abbott Vascular : Coronary physiology            Boston Scientific : Treatment of calcified coronary lesions</p> <hr/> <p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : Complex PCI procedures            Abbott : Coronary physiology            Insight Lifetech : Coronary physiology</p> <hr/> <p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Insight Lifetech : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
Berry Colin	<p><b>2020</b>     <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Menarini : Consultancy through University of Glasgow            Medyria : Consultancy through University of Glasgow            Astrazeneca : Ischaemic heart disease            Abbott Vascular : Ischaemic heart disease, coronary physiology Consultancy through University of Glasgow</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            HeartFlow : Coronary physiology            Abbott Vascular : Ischaemic heart disease            Boehringer Ingelheim : Ischaemic heart disease            GSK : Ischaemic heart disease</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Shares in Kvaatchi Health App - to my knowledge, the company has no business and not operational at this time.</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Berry Colin	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Abbott Vascular : Ischaemic heart disease Astrazeneca : Ischaemic heart disease, COVID-19</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Astrazeneca : COVID-19 HeartFlow : COVID-19 Somalogic : COVID-19 Abbott Vascular : Ischaemic heart disease</p> <p><b>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Media - Kvattchi health app - not active</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Abbott Vascular : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Astrazeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Menarini : Interventional Cardiology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Astrazeneca : CISCO-19 study - biomarkers analyses - ClinicalTrials.gov Identifier: NCT04403607, Chief Investigator Somalogic : CISCO-19 study - biomarkers analyses - ClinicalTrials.gov Identifier: NCT04403607, Chief Investigator HeartFlow : HeartFlow connect, Chief Investigator Abbott Vascular : ICorMicA clinical trial support - ClinicalTrials.gov Identifier: NCT04674449, Chief Investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Berry Colin	<p><b>2022</b></p> <p><b>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Healthcare - Risk Factors and Prevention - Kvaatchi App - a health app company which currently is not in use</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> The University of Glasgow holds intellectual property on the use of zibotentan in microvascular angina. I am a named inventor. No royalties.</p>
Byrne Robert	<p><b>2020</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biotronik : Coronary intervention</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Biosensors : Coronary intervention Boston Scientific : Coronary intervention Abbott Vascular : Coronary intervention</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Women as One Quality, Equity, &amp; Ethical Standards Committee</p> <hr/> <p><b>2021</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Biosensors : Coronary intervention Boston Scientific : Coronary intervention Abbott Vascular : Coronary intervention</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Women as One Quality, Equity, &amp; Ethical Standards Committee</p> <hr/> <p><b>2022</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Biosensors : Clinical trial activity, Principal investigator Boston Scientific : Research/educational grant to institution of employment to support fellowship programme, Clinical director Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Clinical director</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Byrne Robert	<p><b>2022</b></p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> ESC representative at Biomedical Alliance Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Deputy Editor at EuroIntervention Guest Editor at Circulation</p>
Chieffo Alaide	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boston Scientific : Coronary Abbott Vascular : coronary physiology Magenta : high risk PCI Abiomed : High Risk PCI and Cardiogenic Shock Biosensors : stents Edwards Lifesciences : TAVi</p> <p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boston Scientific : Coronary Abbott : coronary physiology Abiomed : High Risk PCI and Cardiogenic Shock Edwards Lifesciences : TAVi</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Abiomed : high risk PCI</p> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Abiomed : Acute Heart Failure Boston Scientific : Chronic Heart Failure Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Biosensors : Valvular Heart Disease Medtronic : Valvular Heart Disease</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Claeys Marc	<p><b>2020</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : antithrombotic/antiplatelet            Astra Zeneca : anti-thrombotic/antiplatelet            Sanofi Aventis : lipid disorders            Abbott Vascular/StJude : stents- mitraclip</p>
	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : antithrombotic/antiplatelet            Astra Zeneca : anti-thrombotic/antiplatelet            Sanofi Aventis : lipid disorders            Abbott Vascular/StJude : stents- mitraclip</p>
	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Atrial Fibrillation (AF), Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes, Pharmacology and Pharmacotherapy            Abbott Vascular/StJude : Valvular Heart Disease, Device Therapy</p>
Coughlan Jj	<p><b>2020</b>     Nothing to be declared</p>
	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Translumina Therapeutics : Consultancy: Coronary Stents</p>
	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Translumina Therapeutics : Interventional Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Dan Gheorghe Andrei	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b></p> <p>Astra Zeneca : speaker-fee, consultancy</p> <p>Bayer : speaker-fee, consultancy</p> <p>Boehringer-Ingelheim : speaker-fee, consultancy</p> <p>Pfizer : speaker-fee, consultancy</p> <p>Servier : speaker-fee, consultancy</p> <p>Sanofi Aventis : speaker-fee, consultancy</p> <p>Zentiva : speaker-fee, consultancy</p> <p>Krka Pharma : speaker-fee, consultancy</p>
	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b></p> <p>Bayer : speaker-fee, consultancy</p> <p>Boehringer-Ingelheim : speaker-fee, consultancy</p> <p>Novartis : speaker-fee, consultancy</p> <p>Pfizer : speaker-fee, consultancy</p> <p>Servier : speaker-fee, consultancy</p> <p>Berlin Chemie AG : speaker-fee, consultancy</p> <p>Zentiva : speaker-fee, consultancy</p> <p>Krka Pharma : speaker-fee, consultancy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Dan Gheorghe Andrei	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Atrial Fibrillation (AF)            Berlin Chemie AG : Atrial Fibrillation (AF)            Boehringer-Ingelheim : Atrial Fibrillation (AF), Chronic Heart Failure            Krka Pharma : Pharmacology and Pharmacotherapy            Novartis : Risk Factors and Prevention            Sanofi Aventis : Risk Factors and Prevention            Amgen Inc : Risk Factors and Prevention</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Boehringer-Ingelheim : European Society of Cardiology</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            Member of the Cardiology Consultant Commission of the Health Ministry, Romania</p>
Dweck Marc	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Novartis : Advisory Boards            Pfizer : Speaking fees (cardiac amyloidosis)</p> <p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Beren : Advisory Board            Silence Therapeutics : Advisory board (aortic stenosis)            Jupiter Bioventures : Advisory Boards (coronary atherosclerosis)            Novartis : Advisory Boards, Speaker Fees (aortic stenosis, coronary atherosclerosis)            Pfizer : Speaking fees (cardiac amyloidosis)</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Dweck Marc	<p><b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Novartis : Cross-Modality and Multi-Modality Imaging Topics Pfizer : Myocardial Disease, Risk Factors and Prevention</p> <p><b>Research funding (personal) from healthcare industry.</b> Novartis : PI IN UK FOR VICTORION PLAQUE STUDY, PI in UK</p>
Galbraith Mary	<p><b>2020</b> <b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Patient Rep/Trustee SHARP (Scottish Heart and Arterial disease Risk Prevention Charity) Division of Molecular &amp; Clinical Medicine Mailbox 1, Level 7, University of Dundee Ninewells Hospital &amp; Medical School Dundee, DD1 9SY</p> <p><b>2021</b> <b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Patient Rep/Trustee SHARP (Scottish Heart and Arterial disease Risk Prevention Charity) Division of Molecular &amp; Clinical Medicine Mailbox 1, Level 7, University of Dundee Ninewells Hospital &amp; Medical School Dundee, DD1 9SY</p> <p><b>2022</b> Nothing to be declared</p>
Gilard Martine	<p><b>2020</b> Nothing to be declared</p> <p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Member of the board of French Society of Cardiology Member of the board of EAPCI Member of the nominating committee of ESC</p>
Hinterbuchner Lynne	<p><b>2020</b> Nothing to be declared</p> <p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> Nothing to be declared</p>
Ibanez Borja	<p><b>2020</b> Nothing to be declared</p> <p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> <b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomina, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Jankowska Ewa Anita	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : anticoagulants, vericiguat            Astra Zeneca : antiplatelets, dapagliflozine            Boehringer-Ingelheim : diabetes and CVD, empagliflozine            Sanofi Aventis : Fabry disease            Abbott : FMR in heart failure            Cardiac Dimensions : heart failure devices            Vifor International : IV iron            Respicardia : phrenic nerve stimulation in CSA            Novartis : sacubitril/valsartan</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Vifor International : iv iron</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Payment from University of Zurich for lectures during the Postgraduate HF Course. Payment from NCBIR (Polish public entity) for research activities in the area of telemedicine in heart failure and non coding RNA</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Jankowska Ewa Anita	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : anticoagulants, vericiguat            Astra Zeneca : antiplatelets, dapagliflozine            Pfizer : Cardiomyopathies            Takeda Pharmaceuticals : Cardiomyopathies            Boehringer-Ingelheim : diabetes and CVD, empagliflozine            Abbott : FMR in heart failure            Servier : heart failure            translational medicine academy : heart failure            Cardiac Dimensions : heart failure devices            Vifor International : IV iron            Swixx Biopharma : iv iron            Respicardia : phrenic nerve stimulation in CSA            Novartis : sacubitril/valsartan</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Vifor International : iv iron</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Payment from University of Zurich for lectures during the Postgraduate HF Course. Payment from NCBIR (Polish public entity) for research activities in the area of telemedicine in heart failure and non coding RNA</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Jankowska Ewa Anita	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott : Chronic Heart Failure            Astra Zeneca : Chronic Heart Failure            Bayer : Chronic Heart Failure            Boehringer-Ingelheim : Chronic Heart Failure            Novartis : Chronic Heart Failure            Cardiac Dimensions : Chronic Heart Failure            Pharmacosmos : Chronic Heart Failure            Servier : Chronic Heart Failure, Acute Heart Failure            Vifor International : Chronic Heart Failure, Acute Heart Failure            Swixx Biopharma : Chronic Heart Failure, Acute Heart Failure            Takeda Pharmaceuticals : Chronic Heart Failure, Other            Respicardia : Device Therapy, Chronic Heart Failure            translational medicine academy : Device Therapy, Chronic Heart Failure, Acute Heart Failure            Pfizer : Other            Sanofi Aventis : Other</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Boehringer-Ingelheim : Chronic Heart Failure</p>
Juni Peter	<p><b>2020</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Fresenius Nutrition : ECCO2R in COPD            Ava : Fertility App            Appili Therapeutics : Infectious Diseases            Amgen Inc : PCSK9 inhibitors in Patients at Cardiovascular Risk</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Juni Peter	<p><b>2020</b></p> <p><b>Employment in healthcare industry (including part time) during the year for which you are declaring.</b> Director, Applied Health Research Centre, St. Michael's Hospital Scientific Director, Ontario COVID-19 Science Advisory Table</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Peter Jüni serves as unpaid member of the steering group of trials funded by Abbott Vascular, Astra Zeneca, Biotronik, Biosensors, St. Jude Medical, Terumo and The Medicines Company, has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and honoraria to the institution for participation in advisory boards and/or consulting from Amgen, Ava and Fresenius, but has not received personal payments by any pharmaceutical company or device manufacturer.</p>
	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Hicks Morley Hamilton Stewart Storie LLP : Expert witness on COVID-19 vaccine mandates for 2 public employers City of Toronto : Expert witness on COVID-19 vaccine mandates for a public employer Baker McKenzie LLP : Expert witness on COVID-19 vaccine mandates for a public employer</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Various: Task 54, Defense Research Development Canada, Department of National Defense, Ottawa, Canada; St Michael's Hospital Foundation, Toronto, Canada; St Joseph's Health Centre Foundation, Toronto, Canada; International Network of Venous Thromboembolism : Coagulopathy of COVID-19: a Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care. Co-PI. Fresenius Nutrition : ECCO2R in COPD Ava : Fertility App Appili Therapeutics : Infectious Diseases Amgen Inc : PCSK9 inhibitors in Patients at Cardiovascular Risk</p> <p><b>Employment in healthcare industry (including part time) during the year for which you are declaring.</b> Director, Applied Health Research Centre, St. Michael's Hospital Scientific Director, Ontario COVID-19 Science Advisory Table</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Juni Peter	<p><b>2022</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Abbott Vascular, Terumo Dr. Jüni serves as unpaid member of committees of trials funded by Abbott Vascular (EXCEL trial: <a href="https://clinicaltrials.gov/ct2/show/NCT01205776">https://clinicaltrials.gov/ct2/show/NCT01205776</a>; comparing XIENCE Stent in subjects with unprotected left main coronary artery disease with coronary artery bypass graft surgery; no active involvement for &gt;3 years, no co-authored publication, but still listed as original member of statistical executive committee) and Terumo (MASTER DAPT trial: <a href="https://www.clinicaltrials.gov/ct2/show/NCT03023020">https://www.clinicaltrials.gov/ct2/show/NCT03023020</a>; comparing abbreviated DAPT with prolonged DAPT in patients with a drug-eluting stent; ongoing active involvement as member of steering group).</p>
Kimura Takeshi	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Abbott Medical Japan LLC. : consultancy Life Science Publishing : Editorial board fees Otsuka Pharmaceutical Co., Ltd. : honoraria Heartflow Japan G.K. : honoraria Astellas Pharma : honoraria Kyowa Hakko Kirin Co., Ltd. : honoraria Pfizer Japan Inc : honoraria Boston Scientific Japan Corporation : honoraria Nippon Boehringer Ingelheim Co ., Ltd. : honoraria, consultancy Kowa Company, Limited : speaker fees</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Nipro : Research Grant W. L. Gore &amp; Associates G.K. : Research Grant Pfizer R&amp;D Japan G.K. : Research Grant CMIC HOLDINGS CO.,Ltd. : Research Grant</p> <hr/> <p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Abbott Medical Japan LLC : advisory board fees</p> <p><b>Research funding (personal) from healthcare industry.</b> Bayer Yakuhin, Ltd. : Contract research expenses</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kimura Takeshi	<p><b>2022</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Boston Scientific : OPTIVUS Complex PCI, Chief investigator            Abbott : STOPDAPT=3, Chief investigator</p>
Kunadian Vijay	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : Digital health, antithrombotic therapy            Abbott Vascular : Stent trial Xience Short DAPT UK Chief Investigator</p>
	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : Anticoagulation            Astra Zeneca : COPD and CVD            Medtronic : Drug coated balloons lecture            Sanofi Aventis : Lecture, women and heart disease</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Medtronic : Acute Coronary Syndromes            Bayer AG : Acute Coronary Syndromes</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Bayer AG : Acute Coronary Syndromes</p>
Leosdottir Margret	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Novo-Nordisk : Speaker fees</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Pfizer : Investigator-initiated study funding</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Leosdottir Margret	<p><b>2020</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Steering group member of SWEDEHEART, the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies quality registry. Chairman of the SEPHIA (Secondary Prevention after Heart Intensive Care Admission) working group - the SWEDEHEART secondary prevention sub-registry. Chairman of a working group for writing national guidelines on secondary prevention in Sweden. Signed a role as investigator in an Astra-Zeneca sponsored RRCT (DAPA-MI trial) in 2020. Recruitment did not start until 2021, however.</p>
	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Speaker fees Novo-Nordisk : Speaker fees Bonnier Healthcare : Writing of an ESC congress report for a continuous education website owned by the company</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> For the assignments listed in 1.A, these were conducted in 2021 while payments will be received in 2022. Other potentially conflicting assignments: Steering group member of SWEDEHEART, the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies quality registry. Chairman of the SEPHIA (Secondary Prevention after Heart Intensive Care Admission) working group - the SWEDEHEART secondary prevention sub-registry. Chairman of a working group for writing national guidelines on secondary prevention in Sweden. Signed a role as investigator in an Astra-Zeneca sponsored RRCT (DAPA-MI trial) in 2020. Recruitment did not start until 2021, however.</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure, Acute Heart Failure Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Novo-Nordisk : IIS grant of 22.000 Euros. The grant is to cover costs of a PhD student under my supervision. , Chief investigator</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Lorusso Roberto	<p><b>2020</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Medtronic : Extracorporeal Life Support            Maquet : Extracorporeal Life Support            Eurosets : Extracorporeal Life Support            Livanova : Extracorporeal Life Support - Cardiac valve</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Medtronic : Extracorporeal Life Support</p>
	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abiomed : Mechanical circulatory support</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Medtronic : Extracorporeal Life Support            GETINGE : Extracorporeal Life Support            Eurosets : Extracorporeal Life Support            Fresenius : Extracorporeal Life Support            Livanova : Extracorporeal Life Support - Cardiac valve            CORCYM : Heart valve disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Medtronic : Extracorporeal Life Support</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Lorusso Roberto	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abiomed : Acute Heart Failure            XENIOS : Acute Heart Failure</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Medtronic : Acute Heart Failure            Livanova : Acute Heart Failure            Eurosets : Acute Heart Failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Medtronic : Research grant on the circulatory support for acute right ventricular failure in animal model, Principal Investigator</p>
Pedretti Roberto Franco Enrico	<p><b>2020</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bristol Myers Squibb : DOACs</p> <p><b>2021</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bristol Myers Squibb : Post-CABG Atrial Fibrillation</p> <p><b>2022</b></p> <p>Nothing to be declared</p>
Rigopoulos Angelos	<p><b>2020</b></p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            HOCM.de</p> <p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Medivibe (Abiomed) : Mechanical LV support with Impella - proctoring fees</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            HOCM.de</p> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Myocardial Disease</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Menarini : Valvular Heart Disease, Myocardial Disease</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Rigopoulos Angelos	<b>2022</b>	<b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> BMC Cardiovascular Disorders Editorial Board Cells Editorial Board Hearts Editorial Board Vice-Chair WG on Cardiomyopathies and Basic Research of the Hellenic Society of Cardiology
Rossello Francisco Javier	<b>2020</b>	Nothing to be declared
	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Rubini Gimenez Maria	<b>2020</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Siemens Healthcare : Biomarkers OrthoClinical Diagnostics : Biomarkers Roche Diagnostics : Biomarkers quidel : Biomarkers
	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Siemens Healthcare : Biomarkers OrthoClinical Diagnostics : Biomarkers Roche Diagnostics : Biomarkers quidel : Biomarkers
	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Siemens Healthcare : Acute Coronary Syndromes OrthoClinical Diagnostics : Acute Coronary Syndromes Roche Diagnostics : Acute Coronary Syndromes quidel : Acute Coronary Syndromes
Thiele Holger	<b>2020</b>	<b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> German Cardiac Society Board of Directors

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Thiele Holger	<b>2021</b> <b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> President elect of German Cardiac Society 2023-2025
	<b>2022</b> <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> I am the incoming president of the German Cardiac Society
Vranckx Pascal	<b>2020</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> CIS-Bhering : Lipid lowering drugs Daiichi Sankyo : Oral anticoagulants Bayer AG : Oral Anticoagulants  <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Daicchi Sankyo : Oral anticoagulants
	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Daiichi Sankyo : NOAC  <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Novartis : Lipids
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Daiichi Sankyo : Atrial Fibrillation (AF)

## 2023 ESC Guidelines for the management of acute coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Wassmann Sven	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b></p> <p>Amgen : Cardiovascular</p> <p>Astra Zeneca : Cardiovascular</p> <p>Boehringer-Ingelheim : Cardiovascular</p> <p>Daiichi Sankyo : Cardiovascular</p> <p>Novartis : Cardiovascular</p> <p>Pfizer : Cardiovascular</p> <p>Lilly : Cardiovascular</p> <p>Berlin Chemie AG : Cardiovascular</p> <p>Bristol Myers Squibb : Cardiovascular</p> <p>Merck Sharp &amp; Dohme : Cardiovascular</p> <p>Bayer Vital : Cardiovascular</p> <p>Apontis : Cardiovascular</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Wassmann Sven	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b></p> <p>Amgen : Cardiovascular</p> <p>Astra Zeneca : Cardiovascular</p> <p>Boehringer-Ingelheim : Cardiovascular</p> <p>Daiichi Sankyo : Cardiovascular</p> <p>Novartis : Cardiovascular</p> <p>Pfizer : Cardiovascular</p> <p>Lilly : Cardiovascular</p> <p>Berlin Chemie AG : Cardiovascular</p> <p>Bristol Myers Squibb : Cardiovascular</p> <p>Merck Sharp &amp; Dohme : Cardiovascular</p> <p>Bayer Vital : Cardiovascular</p> <p>Apontis : Cardiovascular</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Wassmann Sven	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Amgen : Pharmacology and Pharmacotherapy            Astra Zeneca : Pharmacology and Pharmacotherapy            Boehringer-Ingelheim : Pharmacology and Pharmacotherapy            Daiichi Sankyo : Pharmacology and Pharmacotherapy            Novartis : Pharmacology and Pharmacotherapy            Pfizer : Pharmacology and Pharmacotherapy            Lilly : Pharmacology and Pharmacotherapy            Berlin Chemie AG : Pharmacology and Pharmacotherapy            Vifor International : Pharmacology and Pharmacotherapy            Bristol Myers Squibb : Pharmacology and Pharmacotherapy            Bayer Vital : Pharmacology and Pharmacotherapy            Apontis : Pharmacology and Pharmacotherapy</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            Bundesverband Niedergelassener Kardiologen, Germany</p>
Wenger Nanette	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Department of Defence (DoD) : Chair DSMB            NHLBI : Chair DSMB, member DSMB            Amarin : Consultantship            Boehringer-Ingelheim : Research grant            Zoll Medical : Research grant            Duke Clinical Research Institute : Research Grant            Astra Zeneca : Research Grant Consultantship</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Wenger Nanette	<p><b>2020</b></p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> American Heart Association, American College of Cardiology, WomenHeart, Society for Women's Health Research, International Society for Cardiovascular Disease Prevention, American Association for Cardiovascular and Pulmonary Rehabilitation, American Society for Preventive Cardiology, American College of Physicians</p>
	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Department of Defence (DoD) : Chair DSMB NHLBI : Chair DSMB, member DSMB Amarin : Consultantship Boehringer-Ingelheim : Research grant Zoll Medical : Research grant Duke Clinical Research Institute : Research Grant Astra Zeneca : Research Grant Consultantship</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> American Heart Association, American College of Cardiology, WomenHeart, Society for Women's Health Research, International Society for Cardiovascular Disease Prevention, American Association for Cardiovascular and Pulmonary Rehabilitation, American Society for Preventive Cardiology, American College of Physicians</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Duke Clinical Research Institute : Chronic Heart Failure Department of Defence (DoD) : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) NHLBI : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : Advisory board fees            Astra Zeneca : speaker fees            Boehringer-Ingelheim : speaker fees            Novartis : speaker fees</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : Chronic Heart Failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Pfizer : Grant for the cardiology department Cairo University for research project : Screening for cardiac amyloidosis in patients with unexplained LVH , Principal investigator</p>
Aboyans Victor	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer Healthcare : Antithrombotic therapies            Novo-Nordisk : Diabetes            Astrazeneca : Diabetes            Boehringer Ingelheim : Diabetes</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            Member of the French Society of Cardiology</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astrazeneca : Chronic Heart Failure            Bayer Healthcare : Peripheral Vascular and Cerebrovascular Disease, Risk Factors and Prevention            Novo-Nordisk : Risk Factors and Prevention            Amarin : Risk Factors and Prevention            Boehringer Ingelheim : Risk Factors and Prevention</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Aboyans Victor	<b>2022</b> <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> I am a board member of the French Society of Cardiology, and the French Federation of Cardiology
Abramowitz Yigal	<b>2021</b> Nothing to be declared
	<b>2022</b> Nothing to be declared
Ajmone Marsan Nina	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Philips : Ultrasound GE Healthcare : Ultrasound Abbott Vascular : Valvular Heart Disease and Heart Failure <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Alnylam : Cardiac amyloidosis
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> GE Healthcare : Echocardiography Philips Ultrasound : Echocardiography Abbott Vascular : Valvular Heart Disease <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Pfizer : prospective study on cardiac amyloidosis patients, principal investigator Alnylam : retrospective study on cardiac amyloidosis patients, principal investigator
Almeida Manuel De Sousa	<b>2021</b> <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boston Scientific : Interventional Cardiology Medtronic : Interventional Cardiology Terumo Inc : Interventional Cardiology

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Almeida Manuel De Sousa	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Medtronic : 7 items checked            Terumo Inc : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes            Boston Scientific : Valvular Heart Disease, Interventional Cardiology, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes</p>
Angel Kristin	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Antoniou Sotiris	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : speaker fees for education - AF            Bayer AG : speaker fees for education - AF            Daiichi Sankyo : speaker fees for education -AF            Astra Zeneca : speaker fees for education - CVD            Boehringer-Ingelheim : speaker fees for education - CVD</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Astra Zeneca : Joint working initiative on improving CV care</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            Member of Arrhythmia alliance medical advisory panel</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Antoniou Sotiris	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Atrial Fibrillation (AF)            Bayer AG : Atrial Fibrillation (AF), Acute Coronary Syndromes            Boehringer-Ingelheim : Atrial Fibrillation (AF), Chronic Heart Failure            Daiichi Sankyo : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy            Astra Zeneca : Chronic Heart Failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Amarin : development of post MI virtual follow up, Lead investigator            Novartis : joint working collaboration on CVD prevention , principal lead</p>
Asteggiano Riccardo	<p><b>2021</b></p> <p><b>Receipt of royalties for intellectual property.</b>            Council of Cardio-Oncology ESC : cardio-oncology</p> <hr/> <p><b>2022</b></p> <p>Nothing to be declared</p>
Back Maria	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Amgen : Secondary prevention, with focus on education and exercise            Astra Zeneca : Secondary prevention, with focus on education and exercise            Sanofi Aventis : Secondary prevention, with focus on education and exercise</p> <hr/> <p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Amgen : Rehabilitation and Sports Cardiology            Astra Zeneca : Rehabilitation and Sports Cardiology            Sanofi Aventis : Rehabilitation and Sports Cardiology            Bayer AG : Rehabilitation and Sports Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Bajric Mugdim	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> University Tuzla : Internal medicine PRIVATE MEDICAL OFFICE CARDIOLAB TUZLA : INTERNAL MEDICINE University clinical center Tuzla : Invasive cardiology-regular job duties- employee</p> <p><b>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Healthcare - OTHER - DIRECT OWNERSHIP OF PRIVATE INTERNAL MEDICINE MEDICAL OFFICE CALLED CARDIOLAB, STATIONED IN TUZLA, BOSNIA AND HERZEGOVINA. MEDICAL OFFICE PROVIDES SERVICES WITHIN INTERNAL MEDICINE TO INCLUDE ECHOCARDIOLOGY, NON INVASIVE CARDIOLOGY DIAGNOSTICS (HOLTER MONITORING, ERGOMETRY), BASIC CARDIOLOGICAL EXAMS.</p> <p><b>Employment in healthcare industry (including part time) during the year for which you are declaring.</b> Chief of Clinic for invasive cardiology , which includes management duties and interventional cardiologists (MD) duties. Medical doctor at the Cardiolab Tuzla medical office. My position is not in competition with ESC.</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> University Tuzla : Clinical Skills University clinical center Tuzla : Clinical Skills, Arrhythmias, General, Acute Coronary Syndromes, Acute Cardiac Care PRIVATE MEDICAL OFFICE CARDIOLAB TUZLA : Clinical Skills, Arrhythmias, General, Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Hypertension</p> <p><b>Employment (including part time) in healthcare industry during the year for which you are declaring.</b> University CLINICAL CENTER TUZLA : CARDIOLOGYST</p>
Bani Marjeh Mohammed Yassin	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Banning Adrian Paul	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic Foundation : renal denervation Boston Scientific : stents Abbott Vascular : stents</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Banning Adrian Paul	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : Interventional Cardiology            Abbott Vascular : Interventional Cardiology            Medtronic Foundation : Interventional Cardiology            Miracor : Interventional Cardiology</p>
Becker David	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Antithrombotic therapy            Pfizer : Antithrombotic therapy            Krka Pharma : Atherosclerosis            Bayer Healthcare : Atrial fibrillation            Novo-Nordisk : GLP1-A</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Pfizer : ACC online congress</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            Member of the National Cardiology Advisory Board</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer Healthcare : Atrial Fibrillation (AF)            Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Egis Pharma : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Novartis : History of Cardiology, Chronic Heart Failure</p>
Beishenkulov Medet	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Benlamin Hisham	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Bertelli Luca	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Bouزيد Mohammed El Amine	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Capodanno Davide	<b>2021</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Daiichi Sankyo : Antithrombotic therapy            Terumo Inc : Antithrombotic therapy            Sanofi Aventis : Antithrombotic therapy            Biotronik : STEMI</p> <p><b>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b>            Supplier - Minor shareholder (&lt;2%) at CERC Europe (European Cardiovascular Research Center), a Contract Research Organization (CRO) based in Massy, France.</p>
	<b>2022</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Terumo Inc : Interventional Cardiology            Chiesi Pharma : Interventional Cardiology            Amgen : Pharmacology and Pharmacotherapy            Sanofi Aventis : Pharmacology and Pharmacotherapy</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Medtronic : Interventional Cardiology</p>
Casado Arroyo Ruben	<b>2021</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            St Jude Medical : speaker educational fees            Johnson &amp; Johnson : speaker educational fees</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Casado Arroyo Ruben	<p><b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott : Arrhythmias, General            Boston Scientific : Arrhythmias, General</p>
Cassese Salvatore	<p><b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            SIS Medical : Interventional cardiology</p>
	<p><b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes, Interventional Cardiology            SIS Medical : Interventional Cardiology</p>
Celutkiene Jelena	<p><b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : anticoagulation            Boehringer-Ingelheim : heart failure            Novartis : heart failure            Bayer Healthcare : heart failure            Astrazeneca : heart failure</p>
	<p><b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Cardiovascular Disease in Special Populations            Boehringer-Ingelheim : Chronic Heart Failure            Novartis : Chronic Heart Failure            Bayer Healthcare : Chronic Heart Failure            Astrazeneca : Chronic Heart Failure</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Chioncel Ovidiu	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer-Ingelheim : Advisory Board Heart Failure
	<b>2022</b> <b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Servier : Chronic Heart Failure
Chukhrukidze Archil	<b>2021</b> Nothing to be declared
	<b>2022</b> Nothing to be declared
Cikes Maja	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Amyloidosis GE Healthcare : Cardiovascular ultrasound Amicus Therapeutics : Fabry disease Astra Zeneca : Heart failure Bayer : Heart failure Boehringer-Ingelheim : Heart failure Teva Pharmaceutical Industries : Heart failure Krka Pharma : Heart failure Llvanova : Heart failure Novartis : Heart failure, hyperlipidaemia <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> CorVia : Heart failure <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Pfizer : Amyloidosis Abbott : Heart failure Novartis : Heart failure

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Chronic Heart Failure  Bayer : Chronic Heart Failure  Boehringer-Ingelheim : Chronic Heart Failure  Novartis : Chronic Heart Failure  Teva Pharmaceutical Industries : Chronic Heart Failure  Novo-Nordisk : Chronic Heart Failure  Roche Diagnostics : Chronic Heart Failure  Krka Pharma : Chronic Heart Failure  Abbott : Device Therapy  GE Healthcare : Echocardiography  Pfizer : Myocardial Disease  Amicus Therapeutics : Myocardial Disease</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  CorVia : Chronic Heart Failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Abbott : investigator-initiated trial (ENVAD-HF), chief investigator  Novartis : Investigator-initiated trial (ENVAD-HF), chief investigator  Pfizer : National TTR registry, chief investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : post PCI antithrombotic therapy  Pfizer : POST PCI ANTITHROMBOTIC THERAPY  Terumo Inc : POST PCI ANTITHROMBOTIC THERAPY  Bristol Myers Squibb : Post-TAVI antithrombotic treatments</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Medtronic : post tavi antithrombotic therapy  Bristol Myers Squibb : post-tavi antithrombotic therapy</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Acute Coronary Syndromes  Webmed : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  Bristol Myers Squibb : Interventional Cardiology  Medtronic : Valvular Heart Disease</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Medtronic : Valvular Heart Disease</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>  GRCI : <a href="http://www.grci.fr">www.grci.fr</a> France PCI registry : <a href="http://www.francepci.com">www.francepci.com</a> Action Study Group : <a href="http://www.action-groupe.org">www.action-groupe.org</a></p>
Crowley James	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Davlouros Periklis	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Menarini : Hypertension, Angina  Pfizer : NOACS  Bayer : Rivaroxaban  Astra Zeneca : Ticagrelor</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Davlouros Periklis	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Atrial Fibrillation (AF)            Boehringer-Ingelheim : Atrial Fibrillation (AF)            Pfizer : Atrial Fibrillation (AF)            Abbott : Hypertension</p>
Degrell Philippe	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Dobiliene Olivija	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : speaker fees            Bayer : speaker fees            Pfizer : speaker fees            Berlin Menarini : speaker fees            Krka Pharma : speaker fees            Grindeks : speaker fees            Novartis : speaker fees, advisory board fees</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : speaker fees            Servier : speaker fees</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Amgen : congress registration fees            Pfizer : congress registration fees</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Dobiliene Olivija	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Arrhythmias, General            Astra Zeneca : Chronic Heart Failure            Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Berlin Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Grindeks : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Novartis : Risk Factors and Prevention            Krka Pharma : Risk Factors and Prevention            IQVIA : Risk Factors and Prevention</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Novartis : Risk Factors and Prevention</p>
Ducrocq Gregory	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Anticoagulant            Bristol Myers Squibb : Anticoagulant            Astra Zeneca : Heart failure            Abbott : LAA occlusion            Boston Scientific : LAA occlusion            Amgen : Lipid lowering therapy            Sanofi Aventis : Lipid lowering therapy            Novo-Nordisk : Secondary prevention (CEC in a clinical trial, payment not directly by novo)</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Pfizer : Amyloidosis</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ducrocq Gregory	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Acute Coronary Syndromes  Abbott : Atrial Fibrillation (AF)  Boston Scientific : Atrial Fibrillation (AF)  Bristol Myers Squibb : Atrial Fibrillation (AF)  Novo-Nordisk : Chronic Heart Failure  Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  Amgen : Risk Factors and Prevention  Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Pfizer : Funding for research on amyloidosis, Investigator</p>
Elezi Shpend	<p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> Nothing to be declared</p>
Elwasify Tamer Mostafa	<p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Erglis Andrejs	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Amgen : Cardiology            Bayer : Cardiology            Boehringer-Ingelheim : Cardiology            Novartis : Cardiology            Servier : Cardiology            MVRx : Cardiology            Biosensors : Interventional Cardiology            Boston Scientific : Interventional Cardiology            Abbott Vascular : Interventional Cardiology</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            HeartFlow : Interventional Cardiology            Research Company AS "SISTEMU INOVACIJAS" : Interventional Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Erglis Andrejs	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Boehringer-Ingelheim : Atrial Fibrillation (AF)  Novartis : Chronic Heart Failure  Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  Biosensors : Interventional Cardiology  Boston Scientific : Interventional Cardiology  Abbott Vascular : Interventional Cardiology  MVRx : Interventional Cardiology</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  HeartFlow : Interventional Cardiology  Research Company AS “SISTEMU INOVACIJAS” : Interventional Cardiology</p>
Falk Volkmar	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Berlin Heart : Advisory  Novartis : Consultancy  Abbott : Educational Grant for HCP’s  Edwards Lifesciences : Educational Grant for HCP’s  Medtronic : Educational Grant for HCP’s  Cryolife / Jotec : Educational Grant for HCP’s  Boston Scientific : Study  Biotronik : Study  Liva Nova : Study</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Falk Volkmar	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott : Other            Boston Scientific : Other            Edwards Lifesciences : Other            Medtronic : Other            Novartis : Other            Biotronik : Other            Liva Nova : Other            Berlin Heart : Other            Cryolife / Jotec : Other</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            Affiliations: -DZHK - ETH – Zurich, Dept. Health Science &amp; Technology, Transl. Cardiovascular Technology</p>
Fauchier Laurent	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Healthcare            Bayer : Healthcare            Boehringer-Ingelheim : Healthcare            Medtronic : Healthcare            Novartis : Healthcare            BMS/Pfizer : Healthcare            Novo-Nordisk : Healthcare            Zoll Medical : Healthcare            XO : Healthcare</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Fauchier Laurent	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b></p> <p>Astra Zeneca : Pharmacology and Pharmacotherapy</p> <p>Bayer : Pharmacology and Pharmacotherapy</p> <p>Boehringer-Ingelheim : Pharmacology and Pharmacotherapy</p> <p>Novartis : Pharmacology and Pharmacotherapy</p> <p>Servier : Pharmacology and Pharmacotherapy</p> <p>BMS/Pfizer : Pharmacology and Pharmacotherapy</p> <p>Novo-Nordisk : Pharmacology and Pharmacotherapy</p>
Ferreiro Jose Luis	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b></p> <p>Abbott : Antithrombotic therapy</p> <p>Astra Zeneca : Antithrombotic therapy</p> <p>Pfizer : Antithrombotic therapy</p> <p>Ferrer Internacional : Antithrombotic therapy</p> <p>Bristol Myers Squibb : Antithrombotic therapy</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b></p> <p>Biotronik : Interventional Cardiology</p> <p>Terumo Inc : Interventional Cardiology</p> <p>Astra Zeneca : Pharmacology and Pharmacotherapy</p> <p>Pfizer : Pharmacology and Pharmacotherapy</p> <p>Chiesi Pharma : Pharmacology and Pharmacotherapy</p> <p>Ferrer Internacional : Pharmacology and Pharmacotherapy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Geisler Tobias	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bristol Myers Squibb : Anticoagulation, atrial fibrillation, vascular disease            Bayer AG : Anticoagulation, atrial fibrillation, vascular disease            Ferrer Internacional : Antiplatelet therapy, acute coronary syndrome            Medtronic : Valvular disease, TAVR            Edwards Lifesciences : Valvular Heart Disease, Mitral and Tricuspid intervention</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bristol Myers Squibb : Speaker Fees, Honoraria</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Medtronic Foundation : Travel Fees Implanters Meeting</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer AG : Anticoagulation, vascular protection            Bristol Myers Squibb : Anticoagulation, ESUS            Astra Zeneca : Antiplatelet therapy            Medtronic : Atrial fibrillation, ESUS            Thieme Verlag : Editorial Board</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Geisler Tobias	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Pharmacology and Pharmacotherapy  Pfizer : Pharmacology and Pharmacotherapy  Bayer Healthcare : Pharmacology and Pharmacotherapy  Thieme Verlag : Training and Education  Doctrinamed : Training and Education  Edwards Lifesciences : Valvular Heart Disease  Medtronic : Valvular Heart Disease</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Ferrer Internacional : Pharmacology and Pharmacotherapy  Edwards Lifesciences : Valvular Heart Disease</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Daiichi Sankyo : Pharmacology and Pharmacotherapy  Edwards Lifesciences : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Bristol Myers Squibb : ATTICUS trial, Chief investigator  Ferrer Internacional : IIT- Platelet function in cardiogenic shock, Principal investigator  Edwards Lifesciences : IIT, Effects of TEER on Myocardial Remodelling, Principal investigator</p>
Gorog Diana Adrienne	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Speaker fees  Boehringer-Ingelheim : Speaker fees</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Bayer AG : ACS  Alpha MD : ACS  Medtronic : TAVI</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Gorog Diana Adrienne	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Bayer AG : Investigator initiated study, Principal investigator Medtronic : PI for study, PI</p>
GROSU Aurel	<p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> Nothing to be declared</p>
Gudmundsdottir Ingibjorg Jona	<p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> <b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Abbott : Interventional Cardiology Medtronic : Valvular Heart Disease</p>
Halvorsen Sigrun	<p><b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer-Ingelheim : anticoagulation -speaker fee Bristol Myers Squibb : Anticoagulation- speaker fee Novartis : heart failure - speaker fee</p> <p><b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bristol Myers Squibb : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Novartis : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Cardiovascular Disease in Special Populations</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Hassine Majed	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : DYSLIPIDEMIA            Astra Zeneca : DYSLIPIDEMIA AND ANTITRHOBOTIC THERAPY            Novartis : HEART FAILURE            Boehringer-Ingelheim : HYPERTENSION            Daiichi Sankyo : HYPERTENSION            Servier : HYPERTENSION            Menarini : HYPERTENSION            Merck Sharp &amp; Dohme : HYPERTENSION            Sanofi Aventis : HYPERTENSION AND ANTITHROMBOTIC THERAPY            Recordati International : HYPERTENSION AND AOD            Boston Scientific : LAA CLOSURE</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Recordati International : Atrial Fibrillation (AF)            Astra Zeneca : Hypertension            Boehringer-Ingelheim : Hypertension            Servier : Hypertension            Menarini : Hypertension            Merck Sharp &amp; Dohme : Hypertension            Sanofi Aventis : Hypertension, Risk Factors and Prevention</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Hayrapetyan Hamlet	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Servier : Arterial Hypertension, Coronary Heart Disease            Egis Pharma : Arterial Hypertension, Dyslipidemia            Novartis : Heart Failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Tricida Inc. : Chronic Kidney Disease</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Novartis : Chronic Heart Failure            Servier : Hypertension            Egis Pharma : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Servier : RCT, national coordinator</p>
Holmvang Lene	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : antithrombotic therapy            Abbott : PCI</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Microport : Stent</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Idorsia : Acute Coronary Syndromes            Bayer Healthcare : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Abott : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Indolfi Ciro	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Abbott Vascular : devices  General Electric : devices  Amgen : pharmaceuticals  Astra Zeneca : pharmaceuticals  Bayer : pharmaceuticals  Boehringer-Ingelheim : pharmaceuticals  Servier : pharmaceuticals  Johnson &amp; Johnson : pharmaceuticals  Bruno pharmaceuticals : pharmaceuticals</p>
	<p><b>2022</b>     Nothing to be declared</p>
Jaarsma Tiny	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Boehringer-Ingelheim : heart failure</p>
	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Boehringer-Ingelheim : History of Cardiology, Cardiovascular Nursing and Allied Professions</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
James Stefan	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Proctorship</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Swedish medical Association, Swedish cardiac society</p>
Jones Hywel Wynne	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Karamfiloff Kiril	<p><b>2021</b> Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Karamfiloff Kiril	<b>2022</b>	Nothing to be declared
Kober Lars	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Heart Failure Bayer : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Novo-Nordisk : Heart Failure
	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure
Koskinas Konstantinos	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Amgen : Cardiology Daiichi Sankyo : Cardiology  <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Novartis : Cardiology

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Koskinas Konstantinos	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Amgen : Risk Factors and Prevention            Daiichi Sankyo : Risk Factors and Prevention            Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
Kotecha Dipak	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Data Science (Advisory Board)            Amomed : Data Science (Advisory Board)            Protherics Medicines Development : Data Science (Advisory Board)            MyoKardia : Trial Advisory Board</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer : Funding for ESC STEEER-AF trial            Boston Scientific : Funding for ESC STEEER-AF trial            Daiichi Sankyo : Funding for ESC STEEER-AF trial            Boehringer Ingelheim : Funding for ESC STEEER-AF trial            BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial            Amomed : Systematic review            Protherics Medicines Development : Systematic review</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Grants from the UK National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Protherics Medicines Development : Research Methodology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Bayer : Collaborative systematic review of healthcare coding in HF, Principal Investigator Protherics Medicines Development : Grant for independent systematic review, Principal Investigator Bayer : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator Boston Scientific : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator Daiichi Sankyo : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator Boehringer Ingelheim : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator BMS-Pfizer Alliance : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Academic research grants from the National Institute for Health Research (NIHR CDF-2015-08-074; NIHR130280; NIHR132974; NIHR203326); the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032); the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074; including industry collaboration from Bayer, Novartis, Servier, the HYVE and Vifor); and EU Horizon (HYPERMARKER 101095480; including industry collaboration from Roche, MedicineMan and Microlife).</p>
Krychtiuk Konstantin A	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Orion : Cardiogenic Shock, Heart Failure Amgen : Secondary Prevention, Lipids Sanofi Aventis : Secondary Prevention, Lipids</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Orion : Acute Heart Failure Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Krychtiuk Konstantin A	<b>2022</b>	<b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> ACC HeartPAC 2022 attendee
Lakhal Zouhair	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Lancellotti Patrizio	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Landmesser Ulf	<b>2021</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Amgen : Speaker fee            Novartis : Speaker fee            Sanofi Aventis : Speaker fee            Bayer AG : Speaker fee</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Novartis : Lipid Cardio Study            Amgen : Research grant            Bayer AG : Research Grant</p>
	<b>2022</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : Chronic Heart Failure            Amgen : Risk Factors and Prevention            Novartis : Risk Factors and Prevention            Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer AG : COVID PREVENT Study support to institution, Principal Investigator            Novartis : Support of clinical study zo institution, Principal investigator</p>

## 2023 ESC Guidelines for the management of acute coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Lazaros George	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Menerini Hellas : Ranolazine, Coronary atretry disease</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Kiniksa Pharmaceutical : Biological agents in pericarditis</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Roche Diagnostics : Acute Coronary Syndromes Bayer : Pharmacology and Pharmacotherapy Menarini : Pharmacology and Pharmacotherapy</p>
Lewis Basil S	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Idorsia : Antithrombotics Kowa : Lipidology CSL Behring : Lipidology, Secondary prevention</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Kowa : Lipidology</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> CSL Behring : Acute Coronary Syndromes, Pharmacology and Pharmacotherapy Idorsia : Acute Coronary Syndromes, Pharmacology and Pharmacotherapy Janssen R &amp; D : Atrial Fibrillation (AF), Acute Coronary Syndromes, Pharmacology and Pharmacotherapy Anthos : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy</p>
Lindahl Bertil	<p><b>2021</b></p> <p>Nothing to be declared</p>
	<p><b>2022</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Linhart Ales	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Servier : Arterial hypertension, coronary heart disease, heart failure            Boehringer-Ingelheim : Atrial fibrillation, diabetes            Sanofi Aventis : Fabry disease            Takeda Pharmaceuticals : Fabry disease            Avrobio : Faby disease            Novartis : Heart failure</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boehringer-Ingelheim : Chronic Heart Failure            Novartis : Chronic Heart Failure            Servier : Hypertension            Sanofi Aventis : Myocardial Disease            Takeda Pharmaceuticals : Myocardial Disease</p>
Lochen Maja-Lisa	<p><b>2021</b></p> <p>Nothing to be declared</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Sanofi Aventis : Acute Coronary Syndromes            BMS/Pfizer : Atrial Fibrillation (AF)            Bayer AG : Atrial Fibrillation (AF)</p>
Mamas Mamas	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Terumo Inc : speaker fees for webinars. around 1000E a year</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Abbott : pci            Terumo Inc : pci</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mamas Mamas	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Amgen : Acute Coronary Syndromes            Terumo Inc : Interventional Cardiology            Boston Scientific : Other</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Terumo Inc : phd studentship funding for fellow, PhD supervisor</p>
Marandi Toomas	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Lexicon : investigator</p> <hr/> <p><b>2022</b></p> <p>Nothing to be declared</p>
Mcevoy John William	<p><b>2021</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2022</b></p> <p>Nothing to be declared</p>
Mehilli Julinda	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : antithrombotic drugs            Bayer Vital GmbH : antithrombotic drugs            Daiichi Sankyo Europe GmbH : antithrombotic drugs            SIS Medical AG : DEB            Biotronik : DES</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Boston Scientific : TAVI</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mehilli Julinda	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Daiichi Sankyo Europe GmbH : Acute Coronary Syndromes            Astra Zeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Pfizer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Bayer Vital GmbH : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Biotronik : Interventional Cardiology            SIS Medical AG : Interventional Cardiology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Boston Scientific : Institutional research grant, principal investigator</p>
Mercieca Balbi Matthew	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Metzler Bernhard	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Mihaylova Borislava	<p><b>2021</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Merck Sharp &amp; Dohme : Anacetrapib            National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy            Barts Charity : Digital pathology            National Institute for Health Research : Various clinical studies including economic evaluations</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p> <hr/> <p><b>2022</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Merck Sharp &amp; Dohme : economic analyses alongside a clinical trial, senior health economist            Barts Charity : Research project, principal investigator            National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator            Bowel Research UK : research project, principal investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mindham Richard	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> PASSpaces. <a href="http://passpaces.co.uk/">http://passpaces.co.uk/</a>. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> I support the British charity CardiomyopathyUK, <a href="https://www.cardiomyopathy.org.uk/">https://www.cardiomyopathy.org.uk/</a>. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, <a href="https://pumpingmarvellous.org/">https://pumpingmarvellous.org/</a>. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, <a href="https://bureaucracyincts.eu/">https://bureaucracyincts.eu/</a>. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase &amp; sale of shares and I do not know whether any shares are in medical companies.</p>
MITSIS Andreas	<p><b>2021</b></p> <p>Nothing to be declared</p>
	<p><b>2022</b></p> <p>Nothing to be declared</p>
Moussallem Nicolas	<p><b>2021</b></p> <p>Nothing to be declared</p>
	<p><b>2022</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b></p> <p>Bayer : Anticoagulants</p> <p>Daiichi Sankyo : Anticoagulants And Lipid lowering</p> <p>Boehringer-Ingelheim : Antidiabetics</p> <p>Astra Zeneca : Anti-Diabetics</p> <p>Idorsia : Antiplatelet therapy</p> <p>Roche Diagnostics : Diagnostics</p> <p>Acon : Diagnostics</p> <p>Osler : Diagnostics</p> <p>Novartis : Heart Failure</p> <p>Sanofi Aventis : Lipid lowering</p> <p>Amgen : Lipid-lowering</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b></p> <p>Novartis : Diagnostics</p> <p>BRAHMS GmbH : Diagnostics</p> <p>OrthoClinical Diagnostics : Diagnostics</p> <p>Abbott Laboratories : Diagnostics</p> <p>Roche Diagnostics : Diagnostics</p> <p>Siemens : Diagnostics</p> <p>quidel : Diagnostics</p> <p>LSI Medience Corporation : Diagnostics</p> <p>Upstream Medical Technologies : Diagnostics, Myocardial ischemia, BASEL VIII</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Roche Diagnostics : Acute Cardiac Care  Amgen : Acute Coronary Syndromes  Sanofi Aventis : Acute Coronary Syndromes  Idorsia : Acute Coronary Syndromes  SpinChip : Acute Coronary Syndromes  Astra Zeneca : Chronic Heart Failure  Boehringer-Ingelheim : Chronic Heart Failure  Novartis : Chronic Heart Failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Astra Zeneca : Conduct of diagnostic studies in patients with possible heart failure, PI  Novartis : Conduct of diagnostic studies in patients with possible heart failure, PI  OrthoClinical Diagnostics : Conduct of diagnostic studies in patients with suspected AMI, PI  Abbott Laboratories : Conduct of diagnostic studies in patients with suspected AMI, PI  Roche Diagnostics : Conduct of diagnostic studies in patients with suspected AMI, PI  Idorsia : Conduct of diagnostic studies in patients with suspected AMI, PI  Upstream Medical Technologies : Conduct of diagnostic studies in patients with suspected AMI, PI  LSI Medience Corporation : Conduct of diagnostic studies in patients with suspected AMI, PI  SpinChip : Conduct of diagnostic studies in patients with suspected AMI, PI</p>
Neubeck Lis	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Pfizer : Atrial fibrillation</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>  Medical advisor to the Atrial Fibrillation Alliance</p>

## 2023 ESC Guidelines for the management of acute coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Neubeck Lis	2022	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Atrial Fibrillation (AF),
Niebauer Josef	2021	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Willmar Schwabe : Effects of crataegus extract on lipid profile and endothelial function
	2022	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Kwizda : Risk Factors and Prevention, Rehabilitation and Sports Cardiology
Nielsen Jens Cosedis	2021	Nothing to be declared
	2022	<b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Niessner Alexander	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : anticoagulation            Daiichi Sankyo : anticoagulation            Pfizer : anticoagulation            Bristol Myers Squibb : anticoagulation            Boehringer-Ingelheim : anticoagulation, antidiabetic therapy            Novo-Nordisk : antidiabetic therapy            Astra Zeneca : antithrombotic therapy, diabetes, heart failure            Lilly : Diabetes            Merck Sharp &amp; Dohme : Diabetes            Gilead : rheumatology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Daiichi Sankyo : anticoagulation            Pfizer : anticoagulation            Astra Zeneca : Diabetes            Boehringer-Ingelheim : diabetes            Novo-Nordisk : Diabetes</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Niessner Alexander	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Pharmacology and Pharmacotherapy            Boehringer-Ingelheim : Pharmacology and Pharmacotherapy            Daiichi Sankyo : Pharmacology and Pharmacotherapy            Pfizer : Pharmacology and Pharmacotherapy            Lilly : Pharmacology and Pharmacotherapy            Bristol Myers Squibb : Pharmacology and Pharmacotherapy            Novo-Nordisk : Pharmacology and Pharmacotherapy            Galapagos Biopharma : Pharmacology and Pharmacotherapy</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Boehringer-Ingelheim : registry, principal investigator            Boston Scientific : registry, principal investigator            Abbott Vascular : registry, principal investigator</p>
Ostadal Petr	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Acute Coronary Syndrome            Sanofi Aventis : Acute Coronary Syndrome            AOP Orphan Pharmaceuticals : Cardiogenic Shock            Amgen : Dyslipidaemia            Novartis : Dyslipidaemia            Edwards Lifesciences : Haemodynamics            Bayer : Ischemic Heart Disease            Maquet : Mechanical Circulatory Support            Abiomed : Mechanical Circulatory Support</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ostadal Petr	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Edwards Lifesciences : Acute Cardiac Care            AOP Orphan Pharmaceuticals : Acute Cardiac Care            Amgen : Acute Coronary Syndromes            Astra Zeneca : Acute Coronary Syndromes            Bayer : Acute Coronary Syndromes            Novartis : Acute Coronary Syndromes            Sanofi Aventis : Acute Coronary Syndromes            Abiomed : Acute Heart Failure            GETINGE : Acute Heart Failure</p>
Paradies Valeria	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Abbott : Research grant to the institution , Principal investigator</p>
Parkhomenko Alexander	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : dapagliflozin            Boehringer-Ingelheim : empagliflozin            Egis Pharma : ezetimibe            Novartis : inclisirane, entresto            Bayer : rivaroxaban            Novo-Nordisk : semaglutide</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Parkhomenko Alexander	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Boehringer-Ingelheim : Atrial Fibrillation (AF), Chronic Heart Failure  Bayer : Atrial Fibrillation (AF), Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure  Astra Zeneca : Chronic Heart Failure, Acute Coronary Syndromes  Novartis : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  Egis Pharma : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  Novo-Nordisk : Risk Factors and Prevention</p>
Pasquet Agnes A	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Daiichi Sankyo : general cardiology  Servier : general cardiology  Philips : imaging</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>  member of the Belgian Society of Cardiology</p> <hr/> <p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Philips : Echocardiography, Interventional Cardiology  Daiichi Sankyo : Hypertension  Servier : Other</p>
Pejkov Hristo	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Petersen Steffen Erhard	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Petersen Steffen Erhard	<b>2021</b>	<p><b>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
	<b>2022</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Circle Cardiovascular Imaging, Inc : Cardiac Magnetic Resonance (CMR), Cardiac Computed Tomography (CT)</p> <p><b>Research funding (personal) from healthcare industry.</b> Neosoft, LLC : Establishment of healthy reference ranges of cardiac volumes using CMR and Neosoft's SuiteHeart software, Principal investigator</p>
Prescott Eva	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Raber Lorenz	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Sanofi Aventis : alirocumab            Amgen : Evolocumab            Novo-Nordisk : GLP agonist            Abbott : Optical coherence tomography            Canon : Optical coherence tomography            Occlutech : pfoo            Medtronic : renal denervation            Astra Zeneca : Ticagrelor</p> <p><b>Research funding (personal) from healthcare industry.</b>            Sanofi Aventis : Atherosclerosis            Regeneron : Atherosclerosis            Infraredx : Atherosclerosis            HeartFlow : CCTA            Abbott : optical coherence tomography            Boston Scientific : stent</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Raber Lorenz	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Canon : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes            Astra Zeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes            Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes            Medtronic : Device Therapy            Abbott : Interventional Cardiology            Occlutech : Interventional Cardiology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Boston Scientific : CONNECT AMI trial, Principal investigator            Abbott Vascular : Optico LM trial, Principal investigator            HeartFlow : OPTICO LM trial, Principal investigator            Infraredx : Pacman AMI trial, Principal investigator            Sanofi Aventis : unrestricted grant for PACMAN AMI trial, Principal investigator</p>
Radsel Peter	<p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> Nothing to be declared</p>
Rakisheva Amina	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Atrial Fibrillatuion            Novartis : Heart Failure</p> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Chronic Heart Failure            Novartis : Chronic Heart Failure            Roche Diagnostics : Chronic Heart Failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ravn-Fischer Annica	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Anticoagulation. Atrial fibrillation            Pfizer : Anticoagulation. Atrial fibrillation            Bristol Myers Squibb : Anticoagulation. Atrial fibrillation            Boehringer-Ingelheim : Anticoagulation. Atrial fibrillation. Heart failure. Diabetes            Novo-Nordisk : Diabetes            Astra Zeneca : Diabetes, Heart failure            Orion : Heart failure            Amgen : Lipids            Sanofi Aventis : Lipids            Novartis : Lipids.</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer : Atherosclerosis</p> <p><b>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b>            Education - Owner of small company focused on health care education</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ravn-Fischer Annica	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Orion : Acute Heart Failure  Amgen : Risk Factors and Prevention  Astra Zeneca : Risk Factors and Prevention  Bayer : Risk Factors and Prevention  Boehringer-Ingelheim : Risk Factors and Prevention  Novartis : Risk Factors and Prevention  Pfizer : Risk Factors and Prevention  Sanofi Aventis : Risk Factors and Prevention  Bristol Myers Squibb : Risk Factors and Prevention  Novo-Nordisk : Risk Factors and Prevention  Amarin : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Bayer : CAD-PAD research, Principal investigator</p>
Rocca Bianca	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Bayer AG : CV prevention in COVID pandemics  SOBI : platelet growth factor</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Bayer AG : anticoagulant (rivaroxaban)</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Aboca SRL : Other</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Bayer AG : study on low dose rivaroxaban, Chief investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Rosano Giuseppe M C	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott Laboratories : Dyslipidaemia            Vifor International : Iron Deficiency            Menarini : Ischaemic heart disease / arterial hypertension            Astra Zeneca : speakers fees</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Chronic Heart Failure            Vifor International : Chronic Heart Failure            Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Abbott Laboratories : Risk Factors and Prevention</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            Scientific Board of Heart Failure Policy Network</p>
Ryodi Essi	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bristol Myers Squibb : Atrial fibrillation            Novo-Nordisk : Diabetes and heart            Vifor International : Heart failure            Pfizer : Oral anticoagulants</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bristol Myers Squibb : Atrial Fibrillation (AF)            Novo-Nordisk : Cardiovascular Disease in Special Populations</p>
Sade L Elif	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : speaker honorarium fee to the University of Baskent</p>
	<p><b>2022</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Sakhov Orazbek	<b>2021</b> <b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Medtronic : Board of Member on Interventional Cardiology
	<b>2022</b> Nothing to be declared
Schiele Francois	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bayer AG : anticoagulant Astra Zeneca : antiplatelet, statins, antidiabetics Lilly : diabetes Novo-Nordisk : diabetes Recordati International : lipid lowering treatment Servier : lipids Mylan : lipids Sanofi Aventis : PCSK9 inhibitor Amgen Inc : PCSK9 inhibitor <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Novartis : heart failure Amgen : PCSK9 i Pfizer : PCSK9i Sanofi Aventis : PCSK9i



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Schiele Francois	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Recordati International : Acute Coronary Syndromes  Servier : Acute Coronary Syndromes, Risk Factors and Prevention  Sanofi Aventis : Acute Coronary Syndromes, Risk Factors and Prevention  Amgen Inc : Acute Coronary Syndromes, Risk Factors and Prevention  Astra Zeneca : Chronic Heart Failure, Risk Factors and Prevention  Novartis : Risk Factors and Prevention  Novo-Nordisk : Risk Factors and Prevention  Bayer AG : Risk Factors and Prevention  Mylan : Risk Factors and Prevention</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Risk Factors and Prevention  Novartis : Risk Factors and Prevention</p>
Siller-Matula Jolanta	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Boehringer-Ingelheim : Anticoagulants  Chiesi Pharma : Antiplatelet therapy</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  AOP Orphan Pharmaceuticals : Arrhythmia</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Siller-Matula Jolanta	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Daiichi Sankyo : Acute Cardiac Care            Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            Chiesi Pharma : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Interventional Cardiology            Biosensors : Interventional Cardiology            Boston Scientific : Interventional Cardiology            P&amp;F : Interventional Cardiology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            AOP Orphan Pharmaceuticals : PI, chief investigator</p>
Sorensen Rikke	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Novo Nordisk Foundation : Research grant for the Dan-DAPT study, an investigator initiated trial. , Sponsor investigator</p>
Sticherling Christian	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Biosense Webster : Ablation            Abbott : Ablation, ICD, Pacemaker            Microport : Defibrillators, Pacemaker            Boston Scientific : Defibrillators, Pacemaker, Ablation            Medtronic : Defibrillators, Pacemaker, Ablation            Biotronik : Defibrillators, Pacemaker, Ablation</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Biotronik : CRM</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Medtronic : Ablation, Loop recorder</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Sticherling Christian	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Biosense Webster : Atrial Fibrillation (AF)            Boston Scientific : Device Therapy            Medtronic : Device Therapy            Microport : Device Therapy            Abbott : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)            Biotronik : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p>
Stojkovic Sinisa	<p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> Nothing to be declared</p>
Storey Robert	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Sanofi Aventis : Antiplatelet therapy            Idorsia : Antiplatelet therapy            Astrazeneca : Antiplatelet therapy, Glucose-lowering therapy            Bristol Myers Squibb/Pfizer : Antithrombotic therapy            Hengrui : Antithrombotic therapy            PhaseBio : Cardiovascular therapeutics            Novartis : Lipid-lowering therapy            Alnylam : Lipid-lowering therapy            CSL Behring : Lipid-lowering therapy            Cytosorbents : Surgical device, antithrombotic therapy</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Glycardial Diagnostics : Cardiovascular biomarker            Cytosorbents : Surgical device, antithrombotic therapy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Storey Robert	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astrazeneca : Acute Coronary Syndromes  Idorsia : Acute Coronary Syndromes  PhaseBio : Acute Coronary Syndromes  Daiichi Sankyo : Atrial Fibrillation (AF)  Bristol Myers Squibb/Pfizer : Atrial Fibrillation (AF)  Cytosorbents : Cardiovascular Surgery  Chiesi Pharma : Interventional Cardiology  Novartis : Risk Factors and Prevention  Sanofi Aventis : Risk Factors and Prevention  Alnylam : Risk Factors and Prevention  CSL Behring : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Astrazeneca : Acute coronary syndromes, Chief investigator  Cytosorbents : Ticagrelor removal in cardiac surgery, Chief investigator</p>
Studencan Martin	<p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> Nothing to be declared</p>
ten Berg Jurrien M	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : ACS  Boehringer-Ingelheim : ACS  Ferrer Internacional : ACS  Bayer : AF  Pfizer : AF</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
ten Berg Jurrien M	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Acute Coronary Syndromes  Daiichi Sankyo : Acute Coronary Syndromes  Ferrer Internacional : Acute Coronary Syndromes  CeleCOR : Acute Coronary Syndromes</p>
Thielmann Matthias	<p><b>2021</b>     Nothing to be declared</p> <hr/> <p><b>2022</b>     Nothing to be declared</p>
Vrints Christiaan Jm	<p><b>2021</b>     Nothing to be declared</p> <hr/> <p><b>2022</b>     Nothing to be declared</p>
Windecker Stephan	<p><b>2021</b>     <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Daiichi Sankyo : Cardiology  Boehringer-Ingelheim : Cardiology  Boston Scientific : Cardiology  Edwards Lifesciences : Cardiology  Janssen-Cilag : Cardiology  Medtronic : Cardiology  Novartis : Cardiology  Pfizer : Cardiology  Servier : Cardiology  Biotronik : Cardiology  Sanofi Aventis : Cardiology  Johnson &amp; Johnson : Cardiology  Vifor International : Cardiology  Bristol Myers Squibb : Cardiology  Merck Sharp &amp; Dohme : Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	<p>Novo-Nordisk : Cardiology  Regeneron : Cardiology  Orpha Suisse : Cardiology  Guerbet AG : Cardiology  Organon : Cardiology  Amgen : Dyslipidemia  Abbott : Invasive Cardiology  Abiomed : Invasive Cardiology  V-Wave : invasive Cardiology  Miracor medical : invasive Cardiology  Astra Zeneca : Thrombo-Cardiology  Bayer AG : Thrombo-Cardiology</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>  Stephan Windecker reports research and educational grants to the institution from Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Janssen-Cilag, Johnson &amp; Johnson, Medicure, Medtronic, Merck Sharp &amp; Dohm, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi-Aventis, Servier, Sinomed, Terumo, Vifor, V-Wave. Stephan Windecker serves as unpaid advisory board member and/or unpaid member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers. He is also member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. Stephan Windecker is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. He is member of the Clinical Study Group of the Deutsches Zentrum für Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is chairperson of the ESC Congress Program Committee and Deputy Editor of JACC CV Interventions.</p> <hr/> <p><b>2022</b> <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Risk Factors and Prevention  Medtronic : Valvular Heart Disease</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	<p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b></p> <p>Boehringer-Ingelheim : Educational Grant , None</p> <p>Bristol Myers Squibb : Educational Grant , None</p> <p>V-Wave : Sponsored studies (Patient fee) , None</p> <p>Novartis : Sponsored studies (Patient fee), Educational Grant , Principal Investigator</p> <p>Idorsia : Sponsored studies (Patient fee), None</p> <p>CSL Behring : Sponsored studies (Patient fee), Principal investigator</p> <p>Abiomed : Sponsored studies (Patient fee), Principal Investigator</p> <p>Amgen : Educational Grant , None</p> <p>Astra Zeneca : Educational Grant , None</p> <p>Daiichi Sankyo : Educational Grant , None</p> <p>B.Braun : Educational Grant , None</p> <p>Bayer AG : Educational Grant , None</p> <p>Fumedica : Educational Grant , None</p> <p>Cordis Medical : Educational Grant , None</p> <p>Novo Nordisk : Educational Grant, None</p> <p>Pfizer : Funding for IIT, Educational Grant , None</p> <p>Regeneron : Funding for IIT, None</p> <p>Guerbet AG : Funding for IIT, None</p> <p>Boston Scientific : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None</p> <p>Biotronik : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None</p> <p>Sanofi Aventis : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None</p> <p>Johnson &amp; Johnson : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None</p> <p>Edwards Lifesciences : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , Principal Investigator</p> <p>Medtronic : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , Principal Investigator</p> <p>Farapulse Inc : Funding for IIT, Sponsored studies (Patient fee), None</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
	<p>Abbott : Funding for IIT, Sponsored studies (Patient fees), Educational Grant , Site investigator            MedAlliance : Sponsored studies (Patient fee), None            Inari Medical : Sponsored studies (Patient fee), None            Miracor medical : Sponsored studies (Patient fee), None            Pharming Tech : Sponsored studies (Patient fee), None</p> <p><b>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b>            Healthcare - Interventional Cardiology - Deutsches Zentrum für Herzkrankheit, CSG Member and Vice-Speaker            Media - JACC CV Interventions, Deputy Editor Up to date, Section Editor</p>	
Wiseth Rune	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Witkowski Adam	<b>2021</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAO)            Medtronic : Evolute aortic valves (TAVI)            Edwards Lifesciences : Sapien aortic valves (TAVI)</p>
	<b>2022</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : Device Therapy            Edwards Lifesciences : Device Therapy            Medtronic : Device Therapy</p>
Yildirim Aylin	<b>2021</b>	<p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Advisory Board Fee</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Bayer : Congress support            Boehringer-Ingelheim : Congress support</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Yildirim Aylin	<b>2022</b> <b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Bayer : Chronic Heart Failure

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Arbelo Elena	2021	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Atrial fibrillation
	2022	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Atrial Fibrillation (AF)
Baigent Colin	2021	<b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Boehringer-Ingelheim : Renal disease
	2022	<b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Boehringer Ingelheim : Grant to the University of Oxford for the EMPA-KIDNEY trial, Co-PI
Borger Michael A	2021	<b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Cryolife : aortic surgery Abbott : heart valve therapy Edwards Lifesciences : heart valve therapy Medtronic : heart valve therapy
	2022	<b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease
Buccheri Sergio	2021	Nothing to be declared
	2022	Nothing to be declared
Ibanez Borja	2021	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ibanez Borja	<p><b>2022</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
James Stefan	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Proctorship</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Prinicpal investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Swedish medical Association, Swedish cardiac society</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kober Lars	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Heart Failure  Bayer : Heart Failure  Boehringer-Ingelheim : Heart Failure  Novartis : Heart Failure  Novo-Nordisk : Heart Failure</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Chronic Heart Failure  Bayer : Chronic Heart Failure  Boehringer-Ingelheim : Chronic Heart Failure  Novartis : Chronic Heart Failure</p>
Koskinas Konstantinos	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Cardiology  Daiichi Sankyo : Cardiology</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Novartis : Cardiology</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Risk Factors and Prevention  Daiichi Sankyo : Risk Factors and Prevention  Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Mcevoy John William	2021	Nothing to be declared
	2022	Nothing to be declared
Mihaylova Borislava	2021	<p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Merck Sharp &amp; Dohme : Anacetrapib            National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy            Barts Charity : Digital pathology            National Institute for Health Research : Various clinical studies including economic evaluations</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p>
	2022	<p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Merck Sharp &amp; Dohme : economic analyses alongside a clinical trial, senior health economist            Barts Charity : Research project, principal investigator            National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator            Bowel Research UK : research project, principal investigator</p>
Mindham Richard	2021	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
	2022	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            PASSpaces. <a href="http://passpaces.co.uk/">http://passpaces.co.uk/</a>. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mindham Richard	<p><b>2022</b></p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> I support the British charity CardiomyopathyUK, <a href="https://www.cardiomyopathy.org.uk/">https://www.cardiomyopathy.org.uk/</a>. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, <a href="https://pumpingmarvellous.org/">https://pumpingmarvellous.org/</a>. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, <a href="https://bureaucracyincts.eu/">https://bureaucracyincts.eu/</a>. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase &amp; sale of shares and I do not know whether any shares are in medical companies.</p>
Neubeck Lis	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Atrial fibrillation</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Medical advisor to the Atrial Fibrillation Alliance</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Atrial Fibrillation (AF),</p>
Nielsen Jens Cosedis	<p><b>2021</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2022</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p>
Pasquet Agnes A	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> member of the Belgian Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Pasquet Agnes A	<p><b>2022</b>     <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Philips : Echocardiography, Interventional Cardiology            Daiichi Sankyo : Hypertension            Servier : Other</p>
Prescott Eva	<p><b>2021</b>     Nothing to be declared</p>
	<p><b>2022</b>     Nothing to be declared</p>
Rakisheva Amina	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Atrial Fibrillatuion            Novartis : Heart Failure</p>
	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Chronic Heart Failure            Novartis : Chronic Heart Failure            Roche Diagnostics : Chronic Heart Failure</p>
Rocca Bianca	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : CV prevention in COVID pandemics            SOBI : platelet growth factor  <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer AG : anticoagulant (rivaroxaban)</p>
	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Aboca SRL : Other  <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer AG : study on low dose rivaroxaban, Chief investigator</p>
Rossello Francisco Javier	<p><b>2021</b>     Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Rossello Francisco Javier	<b>2022</b>	Nothing to be declared
Vaartjes Ilonca	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Vrints Christiaan Jm	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Witkowski Adam	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAO) Medtronic : Evolute aortic valves (TAVI) Edwards Lifesciences : Sapien aortic valves (TAVI)
	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy
Zeppenfeld Katja	<b>2021</b>	<b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Biosense Webster : Research electrophysiology
	<b>2022</b>	<b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)  <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Biosense Webster : investigator initiated research, PI